Technology
Health
Pharmaceutical

Marinus Pharmaceuticals

$3.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (2.57%) Pre-Market
+$0.10 (2.57%) Pre-Market

Why Robinhood?

You can buy or sell MRNS and other stocks, options, ETFs, and crypto commission-free!

About

Marinus Pharmaceuticals, Inc. Common Stock, also called Marinus Pharmaceuticals, is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Read More Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Employees
28
Headquarters
Radnor, Pennsylvania
Founded
2003
Market Cap
204.30M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
854.03K
High Today
$3.96
Low Today
$3.77
Open Price
$3.88
Volume
359.06K
52 Week High
$10.54
52 Week Low
$2.36

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Therapy
Medical
2014 IPO
US

News

Simply Wall StMar 8

What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?

Every investor in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership. Marinus Pharmaceuticals is not a large company by global standards. It has a market capitalization of US$198m, which means it wouldn’t have the attention of many institutional...

431
Guru FocusMar 6

Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet Study) evaluating oral ganaxolone in children with PCDH19-related epilepsy (PCDH19-RE), a rare genetic epilepsy. If successful, the Violet Study is intended to support...

192
MarketBeatFeb 27

Stock Price, News, & Analysis for Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-de...

137

Earnings

-$0.27
-$0.23
-$0.19
-$0.15
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.25 per share
Actual
-$0.24 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.